Stuttgart - Delayed Quote EUR

ABIONYX Pharma SA (609.SG)

Compare
1.2200
+0.0040
+(0.33%)
At close: January 10 at 3:37:14 PM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 609.SG

Recent News: 609.SG

View More
ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Business Wire 3 days ago
ABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined General Meeting on November 28, 2024

ABIONYX Pharma announces the approval of all resolutions put to the vote at its Combined General Meeting on November 28, 2024
Business Wire last month
ABIONYX Pharma Provides an Update on Its Business and Cash Position for the Third Quarter of 2024

ABIONYX Pharma Provides an Update on Its Business and Cash Position for the Third Quarter of 2024
Business Wire last month
ABIONYX Pharma Announces the Main Resolutions Proposed at the Next Combined General Meeting on November 28, 2024, and the Availability of Related Documents

ABIONYX Pharma Announces the Main Resolutions Proposed at the Next Combined General Meeting on November 28, 2024, and the Availability of Related Documents
Business Wire 2 months ago
ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting "Kidney Week"

ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting "Kidney Week"
Business Wire 2 months ago
ABIONYX Pharma Received Positive Feedback from the EMA for CER-001 in LCAT Deficiency

ABIONYX Pharma Received Positive Feedback from the EMA for CER-001 in LCAT Deficiency
Business Wire 2 months ago
ABIONYX Pharma Announces Its 2024 Half-Year Financial Results

ABIONYX Pharma Announces Its 2024 Half-Year Financial Results
Business Wire 3 months ago
ABIONYX Pharma provides an update on its business and cash position for the 1st half of 2024

ABIONYX Pharma provides an update on its business and cash position for the 1st half of 2024
Business Wire 4 months ago
ABIONYX Carries out Successfully a Capital Increase With Cancellation of Preferential Subscription Rights for the Benefit of a Category of Persons Through the Issue of Shares With Warrants for an Amount of c.€3.4 Million

ABIONYX Carries out Successfully a Capital Increase With Cancellation of Preferential Subscription Rights for the Benefit of a Category of Persons Through the Issue of Shares With Warrants for an Amount of c.€3.4 Million
Business Wire 6 months ago
ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting

ABIONYX Pharma announces unanimous approval of all resolutions put to the vote at its Combined General Meeting
Business Wire 6 months ago
ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million

ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million
Business Wire 6 months ago
View More

Related Tickers

PI3.SG Gubra AS
89.80
-1.97%
 
PI3.DU Gubra AS
89.80
-0.44%
 
NAMSW NewAmsterdam Pharma Company N.V.
14.78
+3.50%
 
POLB.L Poolbeg Pharma PLC
5.15
-8.04%
 
SNGX Soligenix, Inc.
3.2000
-2.14%
 
GUBRA.CO Gubra A/S
666.00
-1.48%
 
AUTL Autolus Therapeutics plc
2.3600
-2.07%
 
ZYME Zymeworks Inc.
13.22
-6.44%
 
CVM CEL-SCI Corporation
0.4252
+16.05%
 
MAIA MAIA Biotechnology, Inc.
2.1200
-0.47%